The ongoing projects are listed below.  The projects that have been completed and published are shown the Publications webpage.
 

1. Develop multi-ancestry polygenic risk scores for lung cancer risk.  Lead: Haoyu Zhang, Rayjean Hung, Xihong Lin, Chris Amos, Byun Jinyoung, Li-Shiun Chen, Laura Bierut

2. The changing demographics and outcomes in older patients with lung cancer over time. Lead: Geoff Liu, Wei Xu. Elizabeth Faour, Shabbir Alibhai, Cathi Brown

3. Impacts of long term smoking cessation and risk of lung cancer.  Lead: James McKay, Lani Park, John Field, David Christiani, Chris Amos

4. Identifying circulating proteins that are a causal consequence of genetic liability to poor prognosis using reverse MR. Leads: Philip Haycock, Rayjean Hung, Geoffrey Liu, Karl Smith-Byrne and James Yarmolinsky

5. Association of epidemiological and genetic variables with tumor size at diagnosis in non-small cell lung cancer. Lead: Olga Gorlova, Christopher Amos, Rayjean Hung

6. Comprehensive investigation of lipidomics in lung cancer risk and prognosis. Lead: Beiwen Wu, Rayjean Hung, Geoffrey Liu, Chris Amos et al

7. Cardiorespiratory fitness, physical activity, and sleep in relation to lung cancer risk using a Mendelian randomization approach. Lead: Eleanor Watts, et al. NCI. Cambridge

8. Evaluation of lung cancer PRS transferability from the perspective of uncertainty in individual PRS. Lead: Xinan Wang, David Christiani, Xihong Lin et al

9. Reliable PRS estimation improves the prediction performance of lung cancer risk. Lead:Xinan Wang, David Christiani, Xihong Lin et al

10. Investigating the shared common genetic variation between telomere length and lung cancer. Lead: Ricardo Cortez, James McKay et al

11. Using germline risk variants to understand interactions between cancer and the immune system. Lead: Xin He, Rayjean Hung, Aida Ferreiro et al

12. Identifying germline risk variants to understand risk of lung cancer and smoking cessation measures in former smokers. Lead: Lani Park et al

13. The association of blood pressure with lung cancer incidence: a joint Mendelian Randomization and randomized control trial study. Lead: Karl Smith Bryne, Mattias Johansson et al

14. The association of blood protein biomarkers with lung cancer incidence and survival: a joint Mendelian Randomization and nested case-control study. Lead: Karl Smith Bryne, Mattias Johansson et al

15. Examining the genetic overlap of tobacco use, cannabis use and use disorder, and lung cancer. Lead: Arpana Agrawal, Laura Beirut, et al

16. Genetic landscape analysis of short tandem repeats on the risk and survival of lung cancer. Lead: Mulong Du, David Christiani

17. Mendelian randomization studies of sleep traits and lung cancer risk. Lead: Brigid Lynch, Suzanne Dizon-Suen, James McKay et al at

18. Circulating vitamin E levels and multiple cancers risk: A Mendelian randomization analysis. Lead: David Christiani et al

19. Machine learning methods to identify genetic variants and risk factors that discriminate between never smoking cases and controls. Lead: Monica Reyes, Matthew Schabath, et al

20. Investigating the causal role of genetic variation in white blood cell traits in lung cancer etiology and prognosis. Lead: Linda Kachuri, Rayjean Hung

21. LD Score Analysis of Lung Cancer using Multi-Traits from UK Biobank. Lead: Jacob Edelson, Chris Amos et al

22. Evaluating genetic, clinical, and environmental risk factors for second primary lung cancer.Lead: Summer Han

23. Genetic architecture of lung cancer using machine-learning approaches in genome-wide association studies. Lead: Jinyoung Byun, Chris Amos

24. Genes related to Genetic And Rare lung Diseases (GARD) as risk for LC. Lead: Albert Rosenberg

25. Appraising the causal relevance of DNA methylation in lung cancer through two-sample Mendelian randomization.Lead: Rebecca Richmond, Caroline Relton et al

26. Genetic contributions to lung cancer risk conveyed through inflammatory and immune pathways. Lead: David Christiani

27. Genetic variant associated with mosaic chromosome alterations. Lead: Chao Cheng, Christopher Amos, James Mckay

28. Mendelian randomization study of circulatory microRNAs and risk of lung cancer. Lead: Kostas Tsilidis, Sarah Chen, Rima Mustafa, Marina Evangelou, Mohsen Ghanbari, Rayjean Hung, Abbas Dehghan

29. Mendelian randomization study of allometric anthropometric indices and risk of lung cancer. Lead: Sofia Christakoudi, Emmanouil Bouras, Eleni Boutsikari, Chris Amos, Kostas Tsilidis

30. Identifying germline risk variants to understand risk of lung cancer and smoking cessation measures in former smokers. Lead: S. Lani Park, L. Le Marchand, D. Stram, C. Amos, J. Mckay

31. The association of blood pressure with lung cancer incidence: a joint Mendelian Randomization and randomized control trial study. Lead: K. Smith Byrne, P. Brennan

32. Detecting racial disparities in cancer survival by integrating multiple high-dimensional observational studies. Lead: Y. Li, S. Guha, D. Christiani

33. Illicit drug abuse (opium, cocaine, crack cocaine, phencyclidine, etc.) and lung cancer risk and survival. Lead: M. Zhang, Z. Zhang, R. Hung, P. Boffetta

34. Machine learning methods to identify genetic variants and risk factors that discriminate between never smoking cases and controls. Lead: Monica E. Reyes, Matthew B. Schabath, Travis Gerke, Zuo-Feng Zhang,Qing Lan, Rayjean Hung, Olga Y. Gorlova

35. Vitamin D and lung cancer survival: a Mendelian randomization study. Lead: Mei Jiang, David Christiani, Rayjean Hung, Geoffrey Liu, Wei Xu

36. Mendelian Randomization Study of BMI, and the Moderating Effects on Inflammation, on Survival of Lung Cancer. Lead: Mei Jiang, Rayjean Hung, Chris Amos, Wen Zhou, Geoffrey Liu, Wei Xu

37. Evaluating change in BMI as a predictor for lung cancer risk. Lead: Wen Zhou, Geoffrey Liu, Quinn Ostrum, Jinyoung Byun, Younghun Han, Paul Brennan, Rayjean Hung, Chris Amos

38. Clinical predictors for EGFR mutation in Lung Cancer. Lead: Geoffrey Liu et al

39. Epigenome-wide survival analysis. Lead: D. Christiani

40. Mechanistic models for lung cancer progression. Lead: Marc Chadeau, Imperial

41. Development of a Novel Bayesian Approach for Genetic Association with Next Generation Sequencing (NGS) Data with Application to Lung Cancer. Lead: Jingxiong (Amelia) Xu, Laurent Briollais, Rayjean Hung, Wei Xu, Geoffrey Liu

42. Clinical outcome based on Exome sequencing. Lead: R. Zhang, D. Christiani, et al

43. Molecular overlap between COPD and lung cancer. Lead: M. Obeidat

44. Genome-wide Association Study of Small Cell Lung Cancer. Lead: Jyoti Malhotra, Paolo Boffetta, David Christiani

45. Identification of interacting genetics associated with early age at diagnosis in lung adenocarcinoma. Lead: L. Briollais

46. Tobacco specific constitutes and lung cancer risk. Lead: Zuo-Feng Zhang

47. Genome-Wide Analysis Study of Lung Cancer Survival. Lead: Geoff Liu, Wei Xu, John K Field, Rayjean Hung, et al

48. Somatic and genomic analysis. Lead: Chris Amos

49. Genetics of smoking phenotype and lung cancer among African American. Lead: Dr. Curtis Harris

50. Disease prediction from GWA data - utilising prior information of pathway analysis. Lead: Rayjean Hung, Nilanjan Chatterjie, et al.

51. Risk variant generalizability and effect modification. Lead: Loic Le Marchand et al